CA2265935A1 - Heat shock protein complexes - Google Patents

Heat shock protein complexes

Info

Publication number
CA2265935A1
CA2265935A1 CA002265935A CA2265935A CA2265935A1 CA 2265935 A1 CA2265935 A1 CA 2265935A1 CA 002265935 A CA002265935 A CA 002265935A CA 2265935 A CA2265935 A CA 2265935A CA 2265935 A1 CA2265935 A1 CA 2265935A1
Authority
CA
Canada
Prior art keywords
heat shock
shock protein
protein complexes
column
adp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002265935A
Other languages
French (fr)
Other versions
CA2265935C (en
Inventor
Erik S. Wallen
Jan Roigas
Pope L. Moseley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
The University Of New Mexico
Erik S. Wallen
Jan Roigas
Pope L. Moseley
Science & Technology Corporation @ Unm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27109678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2265935(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/717,239 external-priority patent/US5747332A/en
Application filed by The University Of New Mexico, Erik S. Wallen, Jan Roigas, Pope L. Moseley, Science & Technology Corporation @ Unm filed Critical The University Of New Mexico
Publication of CA2265935A1 publication Critical patent/CA2265935A1/en
Application granted granted Critical
Publication of CA2265935C publication Critical patent/CA2265935C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/30—Polarising elements
    • G02B5/3025—Polarisers, i.e. arrangements capable of producing a definite output polarisation state from an unpolarised input state
    • G02B5/3033—Polarisers, i.e. arrangements capable of producing a definite output polarisation state from an unpolarised input state in the form of a thin sheet or foil, e.g. Polaroid
    • G02B5/3041—Polarisers, i.e. arrangements capable of producing a definite output polarisation state from an unpolarised input state in the form of a thin sheet or foil, e.g. Polaroid comprising multiple thin layers, e.g. multilayer stacks
    • G02B5/305—Polarisers, i.e. arrangements capable of producing a definite output polarisation state from an unpolarised input state in the form of a thin sheet or foil, e.g. Polaroid comprising multiple thin layers, e.g. multilayer stacks including organic materials, e.g. polymeric layers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method for purifying heat shock protein complexes is provided which comprises the steps of adding a solution containing heat shock protein complexes, in which heat shock proteins are associated with peptides, polypeptides, denatured proteins or antigens, to a column containing an ADP matrix to bind the heat shock protein complexes to the ADP matrix and adding a buffer containing ADP to the column to remove the heat shock protein complexes in an elution product.
Additionally a method for synthesizing heat shock protein complexes and purifying the complexes so produced is provided which comprises the steps of adding heat shock proteins to an ADP matrix column to bind them to the matrix, adding a solution of peptides, polypeptides, denatured proteins or antigens to the column to bind them to the heat shock protein as heat shock protein complexes and adding a buffer containing ADP to the column to remove the complexes in an elution product.
CA002265935A 1996-09-20 1997-09-19 Heat shock protein complexes Expired - Fee Related CA2265935C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/717,239 1996-09-20
US08/717,239 US5747332A (en) 1996-09-20 1996-09-20 Methods for purifying and synthesizing heat shock protein complexes
PCT/US1997/016937 WO1998012208A1 (en) 1996-09-20 1997-09-19 Heat shock protein complexes
US08/934,139 US6066716A (en) 1996-09-20 1997-09-19 Purified heat shock protein complexes
US08/934,139 1997-09-19

Publications (2)

Publication Number Publication Date
CA2265935A1 true CA2265935A1 (en) 1998-03-26
CA2265935C CA2265935C (en) 2006-09-05

Family

ID=27109678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002265935A Expired - Fee Related CA2265935C (en) 1996-09-20 1997-09-19 Heat shock protein complexes

Country Status (5)

Country Link
US (5) US6066716A (en)
EP (1) EP0950061A4 (en)
CA (1) CA2265935C (en)
IN (1) IN183280B (en)
WO (1) WO1998012208A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6066716A (en) 1996-09-20 2000-05-23 University Of New Mexico Purified heat shock protein complexes
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6709672B2 (en) * 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
DE1035780T1 (en) * 1997-12-05 2001-02-08 Univ New Mexico Albuquerque METHOD FOR CLEANING HEAT-SHOCK PEPTIDE COMPLEXES
WO2001040292A1 (en) * 1998-11-27 2001-06-07 Novopharm Biotech Inc. Antigen-binding fragments specific for tumor associated antigens
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
AU7743100A (en) * 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) * 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
CA2429196A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US7235649B2 (en) 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
AU2001266694C1 (en) * 2000-06-02 2005-09-01 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
JP5087201B2 (en) * 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ Molecular vaccine with endoplasmic reticulum chaperone polypeptide linked to antigen
GB0021757D0 (en) * 2000-09-04 2000-10-18 Colaco Camilo Vaccine against microbial pathogens
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
JP4384489B2 (en) * 2001-08-20 2009-12-16 ユニバーシティー オブ コネティカット ヘルス センター Method for preparing a composition comprising a heat shock protein or α-2-macroglobulin useful for the treatment of cancer and infectious diseases
JP2005512519A (en) 2001-10-01 2005-05-12 デューク・ユニバーシティ Isolated GRP94 ligand binding domain polypeptide, nucleic acid encoding the same, crystal thereof, and screening method using the same
AU2003223226A1 (en) * 2003-02-20 2004-09-17 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
WO2004098526A2 (en) * 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
WO2008024844A2 (en) * 2006-08-22 2008-02-28 The Johns Hopkins University Anticancer combination therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
PL2659904T3 (en) 2008-06-26 2016-01-29 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
US8986712B2 (en) 2009-11-29 2015-03-24 Yeda Research And Development Co., Ltd. Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation
PL2646044T3 (en) 2010-11-30 2020-03-31 Orphazyme A/S Methods for increasing intracellular activity of hsp70
JP6678676B2 (en) 2014-09-15 2020-04-08 オーファザイム エー／エス Arimoclomol formulation
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
EP3448382B1 (en) 2016-04-29 2020-10-14 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
JPS6344888A (en) * 1986-08-12 1988-02-25 Agency Of Ind Science & Technol Chimera fused oxidase of cytochrome p-450 and nadph-dytochrome p-450 reductase
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
US5268465A (en) * 1991-01-18 1993-12-07 The Johns Hopkins University Purification and molecular cloning of nitric oxide synthase
US5348864A (en) * 1991-01-25 1994-09-20 E. R. Squibb & Sons, Inc. Mouse vav proto-oncogene DNA and protein sequences
US5132407A (en) * 1991-09-26 1992-07-21 Cornell Research Foundation, Inc. Purified inducible nitric oxide synthase flavoprotein
US5541095A (en) * 1992-06-16 1996-07-30 University Of Massachusetts Medical Center Glycosaminoglycan specific sulfotransferases
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5550214A (en) * 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6066716A (en) 1996-09-20 2000-05-23 University Of New Mexico Purified heat shock protein complexes
US5747332A (en) * 1996-09-20 1998-05-05 University Of New Mexico Methods for purifying and synthesizing heat shock protein complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes

Also Published As

Publication number Publication date
US5981706A (en) 1999-11-09
US20020156250A1 (en) 2002-10-24
US6066716A (en) 2000-05-23
US6713608B2 (en) 2004-03-30
WO1998012208A1 (en) 1998-03-26
EP0950061A1 (en) 1999-10-20
CA2265935C (en) 2006-09-05
EP0950061A4 (en) 2000-04-12
IN183280B (en) 1999-10-30
US20040143105A1 (en) 2004-07-22
US6433141B1 (en) 2002-08-13

Similar Documents

Publication Publication Date Title
CA2265935A1 (en) Heat shock protein complexes
CA2183888A1 (en) Antibody purification
CA2275489A1 (en) Oil bodies and associated proteins as affinity matrices
AU642403B2 (en) Method for the use and synthesis of peptides
CA2172376A1 (en) Antibodies to cd40
CA2155185A1 (en) Totally synthetic affinity reagents
EP0832973A3 (en) GTP-binding protein
AU1399495A (en) Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
RU93046317A (en) CHINDROITINASE, METHOD FOR ITS PREPARATION AND CONTENTS OF ITS PHARMACEUTICAL COMPOSITIONS
CA2042945A1 (en) Protein purification method
CA2413156A1 (en) Expression vectors
CA2220447A1 (en) Novel fusion protein recovery and purification methods
WO1992010514A3 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus
AU4453689A (en) Binding protein for insulin-like growth factors
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
CA2173102A1 (en) Dna sequence coding for a bmp receptor
CA2143510A1 (en) Method for the Isolation and Purification of Vitamin K-Dependent Proteins
EP0239311A3 (en) Mutual separation of proteins
AU676277B2 (en) DNA fragment, vector containing the DNA fragment, transformant transformed with the vector and process for producing protein using the vector
AU4375493A (en) Isolated protein receptors, antibodies which bind thereto, nucleic acid sequence coding therefor, and uses thereof
DE3584029D1 (en) EXPRESSION VECTORS, DNA FRAGMENTS, PEPTIDES, HOST AND METHOD FOR PRODUCING PEPTIDES.
CA2176236A1 (en) Tyrosinase-activator protein fusion enzyme
CA2243578A1 (en) High affinity nucleic acid ligands of complement system proteins
AU7796291A (en) High affinity antibodies to small peptides
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130919